Aclarion, Inc. (Nasdaq: ACON, ACONW) announced a second commercial agreement with Weill Cornell Medicine, integrating its Nociscan platform into a new clinical trial led by renowned neurosurgeon Dr. Roger Härtl. The trial, titled “Bone Marrow Aspirate Concentrate Injection with MRI’s – a Prospective Randomized Controlled Trial” (IRB Protocol No. 24-09027977), will evaluate the long-term effects of lumbar microdiscectomy surgery with and without intradiscal bone marrow aspirate concentrate (BMAC) injection. This 2-year prospective study aims to assess patient-reported outcomes, intervertebral disc health, and pain biomarkers, providing insights into the natural history of degenerative disc disease (DDD) and informing less invasive treatment strategies.
“Our scientific interest focuses on clinical and basic science research surrounding innovative and less invasive surgical and biological treatment strategies for degenerative diseases of the spine. This trial strives to enhance our understanding of disc degeneration in patients, and illuminate chemical aspects of disc degeneration not available with traditional imaging,” said Dr. Härtl, the Hansen-MacDonald Professor of Neurological Surgery and Director of Spinal Surgery at Weill Cornell Medicine in New York. The study will be conducted at Weill Cornell Medicine and Och Spine at NewYork-Presbyterian/Weill Cornell Medical Center.
This marks the second trial at Weill Cornell Medicine to incorporate Nociscan, Aclarion’s evidence-supported SaaS platform that noninvasively helps physicians distinguish between painful and nonpainful discs in the lumbar spine. Ryan Bond, Chief Strategy Officer of Aclarion, emphasized the significance of the collaboration: “We are pleased to engage in this trial with Dr. Härtl and his team at Weill Cornell. Not only are Dr. Härtl and his colleagues renowned for their clinical excellence, their commitment to pioneering research is evident through this prospective randomized trial evaluating disc degeneration and the potential effects of bone marrow aspirate concentrate. Progressive trials such as this one are a clear example for how healthcare advances – investigating a major global health issue, like degenerative disc disease, while using innovative tools like Nociscan.”
Chronic low back pain (cLBP) affects approximately 266 million people worldwide, according to a study referenced by the company (Ravindra VM, Global Spine Journal, 2018). Nociscan leverages magnetic resonance spectroscopy (MRS), proprietary signal processing, and augmented intelligence to quantify chemical biomarkers associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain and has demonstrated a 97% surgical success rate when all Nociscan-identified pain-positive discs are treated (Gornet M, Peacock J, et al. European Spine Journal, 2019).
The agreement expands Aclarion’s commercial reach and supports its mission to optimize clinical treatments for chronic low back pain. For more information about Aclarion and Nociscan, visit www.aclarion.com. To find a Nociscan center, view the site map here. For latest news, see https://www.aclarion.com/news.
